Biotech Retrophin, LLC Files For $40 Million IPO
Published: Dec 20, 2013
Retrophin, which is developing treatments for postpartum milk let-down, Schizophrenia and Autism, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The New York, NY-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RTRX. The company is currently traded on the OTCQB under the same ticker.
Help employers find you! Check out all the jobs and post your resume.